Earnings ·
KORU Medical Systems, Inc. reported second quarter fiscal 2026 financial results and updated full-year guidance for…
KRMDKORU Medical Systems, Inc.
KORU Medical Systems, Inc. reported second quarter fiscal 2026 financial results and updated full-year guidance for the year ending December 31, 2025. Net revenues grew 18% to $12.0 million, driven by a 12.4% increase in domestic core sales and a 59.1% surge in international core revenue. Gross profit rose 20% to $7.8 million with a gross margin of 65.1%, while net income improved 222% to $0.25 million, or $0.01 per diluted share. The company adjusted its full-year 2026 revenue guidance to $47.5–$48.5 million and raised gross margin expectations to 62–64%. Strategic updates include withdrawing the U.S. 510(k) application for FreedomEDGE with Phesgo, shifting oncology strategy to higher-volume molecules, acquiring a connected monitoring technology asset, and entering a multi-year supply agreement. KORU Medical Systems operates in the medical device industry, developing and commercializing subcutaneous infusion solutions.